{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:25:12Z","timestamp":1772825112854,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T00:00:00Z","timestamp":1201910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T00:00:00Z","timestamp":1201910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s10637-007-9109-9","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T16:55:15Z","timestamp":1201884915000},"page":"399-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice"],"prefix":"10.1007","volume":"26","author":[{"given":"William C.","family":"Zamboni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Strychor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Fetterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Sidone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis P.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie L.","family":"Eiseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,2]]},"reference":[{"key":"9109_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1006\/abio.1993.1325","volume":"212","author":"TG Burke","year":"1993","unstructured":"Burke TG, Mi Z (1993) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212:285\u2013287","journal-title":"Anal Biochem"},{"key":"9109_CR2","doi-asserted-by":"publisher","first-page":"10325","DOI":"10.1021\/bi00200a013","volume":"33","author":"Z Mi","year":"1994","unstructured":"Mi Z, Burke TG (1994) Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325\u201310336","journal-title":"Biochemistry"},{"key":"9109_CR3","doi-asserted-by":"publisher","first-page":"12540","DOI":"10.1021\/bi00208a002","volume":"33","author":"Z Mi","year":"1994","unstructured":"Mi Z, Burke TG (1994) Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 33:12540\u201312545","journal-title":"Biochemistry"},{"key":"9109_CR4","first-page":"4898","volume":"59","author":"IF Pollack","year":"2001","unstructured":"Pollack IF, Erff M, Bom D et al (2001) Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Can Res 59:4898\u20134905","journal-title":"Can Res"},{"key":"9109_CR5","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1021\/ja00006a033","volume":"113","author":"DP Curran","year":"1991","unstructured":"Curran DP, Liu H (1991) 4\u2009+\u20091 Radical annulations with isonitriles\u2014a simple route to cyclopenta-fused quinolines. J Am Chem Soc 113:2127\u20132132","journal-title":"J Am Chem Soc"},{"key":"9109_CR6","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1021\/jo00100a005","volume":"59","author":"DP Curran","year":"1994","unstructured":"Curran DP, Ko SB (1994) Synthesis of optically active alpha-hydroxy lactones by sharpless asymmetric dihydroxylations of ketene acetals, enol ethers, and ene lactones. J Org Chem 59:6139\u20136141","journal-title":"J Org Chem"},{"key":"9109_CR7","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1016\/S0960-894X(97)10181-0","volume":"7","author":"H Josien","year":"1997","unstructured":"Josien H, Bom D, Curran DP, Zheng YH, Chou T (1997) 7-Silylcamptothecins (Silatecans): a new family of camptothecin antitumor agents. Bioorg Med Chem Lett 7:3189\u20133295","journal-title":"Bioorg Med Chem Lett"},{"key":"9109_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jps.2600840426","volume":"84","author":"TG Burke","year":"1995","unstructured":"Burke TG, Mi Z, Jiang Y, Munshi CB (1995) The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84:518\u2013519","journal-title":"J Pharm Sci"},{"key":"9109_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1021\/jm00027a005","volume":"37","author":"TG Burke","year":"1994","unstructured":"Burke TG, Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40\u201346","journal-title":"J Med Chem"},{"key":"9109_CR10","first-page":"4898","volume":"59","author":"IF Pollack","year":"1999","unstructured":"Pollack IF, Erff M, Bom D et al (1999) Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59:4898\u2013905","journal-title":"Cancer Res"},{"key":"9109_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002800050855","volume":"43","author":"MS Newman","year":"1999","unstructured":"Newman MS, Colbern GT, Working PK et al (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor bearing mice. Cancer Chemother Pharmacol 43:1\u20137","journal-title":"Cancer Chemother Pharmacol"},{"key":"9109_CR12","first-page":"3255","volume":"52","author":"EA Forssen","year":"1992","unstructured":"Forssen EA, Coulter DM, Proffitt RT (1992) Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52:3255\u20133261","journal-title":"Cancer Res"},{"key":"9109_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0169-409X(96)00453-X","volume":"24","author":"EA Forssen","year":"1997","unstructured":"Forssen EA (1997) The design and development of DaunoXome for solid tumor targeting in vivo. Adv Drug Deliv Rev 24:133\u2013150","journal-title":"Adv Drug Deliv Rev"},{"key":"9109_CR14","doi-asserted-by":"publisher","first-page":"8230","DOI":"10.1158\/1078-0432.CCR-05-1895","volume":"11","author":"WC Zamboni","year":"2005","unstructured":"Zamboni WC (2005) Liposomal, nanoparticle, conjugated formulations of anticancer agents. Clin Cancer Res 11:8230\u20138234","journal-title":"Clin Cancer Res"},{"key":"9109_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/jnci\/90.7.505","volume":"90","author":"WC Zamboni","year":"1998","unstructured":"Zamboni WC, Stewart CF, Thompson J et al (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505\u2013511","journal-title":"J Natl Cancer Inst"},{"key":"9109_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00280-003-0719-4","volume":"53","author":"WC Zamboni","year":"2004","unstructured":"Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL (2004) Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329\u2013336","journal-title":"Cancer Chemother Pharmacol"},{"key":"9109_CR17","unstructured":"D\u2019Argenio DZ, Schmuitzky A (1990) ADAPT II User\u2019s Guide: Biomedical Simulations Resource"},{"key":"9109_CR18","volume-title":"Clinical pharmacokinetics: concepts and applications","author":"M Rowland","year":"1999","unstructured":"Rowland M, Tozer T (1999) Clinical pharmacokinetics: concepts and applications. Lea and Febiger, Philadelphia"},{"key":"9109_CR19","doi-asserted-by":"publisher","first-page":"13722","DOI":"10.1021\/bi00042a002","volume":"34","author":"Z Mi","year":"1995","unstructured":"Mi Z, Malak H, Burke TG (1995) Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochem 34:13722\u201313728","journal-title":"Biochem"},{"key":"9109_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/0091270003255921","volume":"43","author":"JA Smith","year":"2003","unstructured":"Smith JA, Newman RA, Hausheer FH, Madden T (2003) Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol 43:1008\u20131014","journal-title":"J Clin Pharmacol"},{"key":"9109_CR21","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ejca.2004.02.016","volume":"40","author":"CJ Punt","year":"2004","unstructured":"Punt CJ, de Jonge MJ, Monfardini S, Daugaard G, Fiedler W, Baron B, Lacombe D, Fumoleau P, EORTC New Drug Development Group (2004) RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. Eur J Cancer 40:1332\u20131334","journal-title":"Eur J Cancer"},{"key":"9109_CR22","doi-asserted-by":"publisher","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","volume":"88","author":"D Papahadjopoulos","year":"1991","unstructured":"Papahadjopoulos D, Allen TM, Gabizon A et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460\u201311464","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9109_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271\u2013284","journal-title":"J Control Release"},{"key":"9109_CR24","unstructured":"Zamboni WC, Strychor S, Joseph E, Walsh DR, Parise RA, Tonda ME, Yu NY, Engber C, Eiseman JE (2005) Plasma and tumor disposition of STEALTH Liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenograft. Proc Am Acad Clin Res-NCI-EORTC: #B173"},{"key":"9109_CR25","first-page":"1280","volume":"47","author":"WC Zamboni","year":"2006","unstructured":"Zamboni WC, Eiseman JE, Strychor S, Rice PM, Joseph E, Potter DM, Shurer J, Walsh DR, Parise RA, Tonda ME, Yu NY, Engber C, Basse PH (2006) Relationship between the plasma and tumor disposition of STEALTH liposomal CKD-602 and macrophages\/dendritic cells (MDC) in mice bearing human tumor xenografts. Proc Am Acad Clin Res 47:1280 (abstract #5449)","journal-title":"Proc Am Acad Clin Res"},{"key":"9109_CR26","first-page":"721","volume":"47","author":"S Strychor","year":"2006","unstructured":"Strychor S, Eiseman JE, Joseph E, Parise RA, Tonda ME, Yu NY, Engber C, Zamboni WC (2006) Plasma, tissue, and tumor disposition of STEALTH liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts. Proc Am Acad Clin Res 47:721 (abstract #3064)","journal-title":"Proc Am Acad Clin Res"},{"key":"9109_CR27","first-page":"82s","volume":"24","author":"WC Zamboni","year":"2006","unstructured":"Zamboni WC, Friedland DM, Ramalingam S, Edwards RP, Stoller RG, Belani CP, Strychor S, Ou YC, Tonda ME, Ramanathan RK (2006) Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 24:82s (abstract #2013)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9109_CR28","unstructured":"National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington DC"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-007-9109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9109-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:31Z","timestamp":1678559551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-007-9109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,2]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["9109"],"URL":"https:\/\/doi.org\/10.1007\/s10637-007-9109-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,2]]},"assertion":[{"value":"1 October 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}